Events & Presentations

Upcoming Events

There are no upcoming events available at this time.

Past Events

23andMe's FY2025 2nd Quarter Earnings Call

November 12, 2024 at 5:00 AM PST

23andMe Q2 FY2025 Earnings Q&A

Click here for webcast

Link to 23andMe's FY2025 2nd Quarter Earnings Call webcast

European Society of Medical Oncology (ESMO) Congress 2024

September 13 - September 17, 2024

Click here for event

Link to European Society of Medical Oncology (ESMO) Congress 2024 webcast

Supporting Materials

23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody, for Patients with Advanced Solid Malignancies 6.8 MB

Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort 19.6 MB

23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcγRIIIa activation 57.5 MB

Phase 1/2a trial of CD200R1 inhibitor 23ME-00610: exploratory analyses of tissue-based and genetic biomarkers 30.2 MB

Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country Phase 1/2a expansion cohort 25.5 MB

23andMe's FY2025 1st Quarter Earnings Call

August 08, 2024 at 1:30 PM PDT

23andMe Q1 FY2025 Earnings Q&A

Click here for webcast

Link to 23andMe's FY2025 1st Quarter Earnings Call webcast

2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 01, 2024

Supporting Materials

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country Phase 1/2a expansion cohort 20.3 MB

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: results from a multi-center multi-country Phase 1/2a expansion cohort 6.6 MB

23andMe's FY2024 4th Quarter Earnings Call

May 23, 2024 at 1:30 PM PDT

23andMe Q4 FY2024 Earnings Q&A

Click here for webcast

Link to 23andMe's FY2024 4th Quarter Earnings Call webcast

American Association for Cancer Research (AACR) Annual Meeting 2024

April 05 - April 10, 2024

Supporting Materials

New Insights into Targeting the CD200R1 Pathway in T and NK Cells Using 23ME-00610 as a Single Agent or in Combination 4.7 MB

23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation 1.9 MB

Discovery of ULBP6 as a Novel Immuno-Oncology Target Using Pleiotropic Signals from 23andMe’s Genetic and Health Survey Database 9.4 MB

TD Cowen 44th Annual Health Care Conference

March 05, 2024 at 9:50 AM EST

23andMe's FY2024 3rd Quarter Earnings Call

February 07, 2024 at 4:30 PM EST

23andMe Q3 FY2024 Earnings Q&A

Click here for webcast

Link to 23andMe's FY2024 3rd Quarter Earnings Call webcast

23andMe's FY2024 2nd Quarter Earnings Call

November 08, 2023 at 4:30 PM EST

Click here for webcast

Link to 23andMe's FY2024 2nd Quarter Earnings Call webcast

Society for Immunotherapy of Cancer Annual Meeting 2023 (SITC)

November 03, 2023 at 9:00 AM PDT

Supporting Materials

Phase 1/2a Dose Selection of 23ME-00610, a First-in-Class Anti-CD200R1 Antibody, in Participants with Advanced Solid Malignancies 1.7 MB

First-in-class Anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies: Updated Phase 1 Results 11 MB

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Presentations

Investor Presentation

2023 Annual Report

2022 ESG Report